Nasdaq notification for Introgen

Introgen Therapeutics, a US developer of targeted molecular therapies for cancer, has received a letter from the Nasdaq Stock Market indicating that, during the preceding 30 consecutive trading days, the closing bid price of its common stock has been below the $1.00 minimum bid price required for continued listing on the under Nasdaq Marketplace Rule 4450(a)(5). This letter has no immediate effect on the listing of Introgen's common stock.

The letter stated that, in accordance with this rule, Introgen will be provided 180 calendar days, or until March 30, 2009, to regain compliance with the minimum bid price requirement by maintaining a closing price of $1.00 per share or higher for a minimum of 10 consecutive trading days.

If Introgen is unsuccessful in meeting the minimum requirements, the Nasdaq will provide notice that the company's common stock will be delisted. Introgen may appeal the determination or, alternatively, it may apply to transfer its common stock to the Nasdaq Capital Market providing the firm satisfies all criteria for initial listing on this, other than compliance with the minimum bid price requirement.